{"gao_id": "GAO-21-52", "published": "2020-10-22T12:00:00Z", "released": "2020-11-20T07:00:00Z", "summary": "Federal research and inventions can contribute to the development of life-saving drugs, vaccines, and medical devices. One way this happens is that the National Institutes of Health licenses its intellectual property to private companies that have the resources to bring products to market. NIH received up to $2 billion in royalties from its contributions to 34 drugs sold from 1991-2019. But how does licensing support...", "title": "Biomedical Research: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property", "topics": ["Reporting requirements", "Technology transfer", "Intellectual property", "Intellectual property rights", "License agreements", "New drugs", "Pharmaceutical industry", "Patents", "Biomedical research", "Science and Technology", "Research and development", "Prescription drugs", "Drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-21-52", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-21-52-highlights.pdf"}, {"title": "Full Report (87 pages)", "url": "https://www.gao.gov/assets/gao-21-52.pdf"}, {"title": "Accessible PDF (106 pages)", "url": "https://www.gao.gov/assets/720/710328.pdf"}]}